TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Steven J. Isakoff(Harvard University), Leif W. Ellisen(Harvard University), Paula D. Ryan(Massachusetts General Hospital), Tiffany A. Traina(Memorial Sloan Kettering Cancer Center), Darrel R. Borger(Harvard University), Minetta C. Liu(Mayo Clinic), Kirsten M. Timms(Myriad (Germany)), Lisa A. Carey(University of North Carolina at Chapel Hill), Vered Stearns(Johns Hopkins University), Dianne M. Finkelstein(Harvard University), Steven E. Come, Lei He(Harvard University), Karen J. Krag, Eric P. Winer(University of Vermont), Erica L. Mayer(Harvard University), Hope S. Rugo(City of Hope), Paul E. Goss(Princess Margaret Hospital), Anne-Renee Hartman(Shaanxi Research Association for Women and Family), Judy E. Garber(Dana-Farber Cancer Institute)
Cited by 433
Related Papers
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k